Femoral Proximal Articles & Analysis
2 articles found
” In May 2020, Alucent initiated a small, Phase I human safety study (ACTIVATE I) of NVS for PAD in the superficial femoral and/or proximal popliteal artery; that study is partly enrolled and will likely need to await resolution of the COVID-19 pandemic before completion. ...
It’s a prospective, nonrandomized, multicenter, open-label study that will assess the safety, pharmacokinetics and preliminary efficacy in applying AlucentNVS therapy to de novo lesions in the superficial femoral artery (SFA) and the proximal popliteal artery (PPA) during percutaneous transluminal angioplasty in patients with claudication due to obstructive ...